Phase 2 Oesophageal Cancer Trial, Recruiting NCT06408116 Sponsor: University Hospital Heidelberg Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06408116
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of oesophageal (food pipe) cancer — either adenocarcinoma or squamous cell carcinoma — confirmed by a laboratory tissue test, including certain tumours where the food pipe meets the stomach (AEG I and AEG II)
  • People for whom surgery to treat the oesophageal cancer is being planned
  • People whose cancer staging (determining how far the cancer has spread) could benefit from a specialised type of scan called a FAPI PET/CT
  • People who are able to carry out basic daily activities independently, with a fitness level meeting a standard medical measure (Karnofsky Index 60% or ECOG score of 0 or 1) (confirm with trial site)
  • People aged 18 years or older
  • People who have received full information about the trial and have provided written agreement to take part

Who may not be able to join:

  • People who have previously had radiation therapy in the area where the tumour is located
  • People who have had a previous cancer diagnosis and have been in remission for fewer than 5 years
  • People for whom surgery is not possible due to their physical condition or technical surgical reasons
  • People whose cancer has spread to distant parts of the body (distant metastasis)
  • People who are not able to give informed consent to participate
  • People who are already participating in another clinical trial that could interfere with the results of either trial
  • People with other illnesses that prevent them from fully understanding what the study involves and what the possible consequences may be
  • People who are pregnant or breastfeeding
  • People who show signs that they are unlikely to follow through with the treatment requirements, such as an unwillingness to cooperate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +496221 56

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University Hospital Heidelberg
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
1 January 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Tumor expansion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov